Vorinostat, an inhibitor of class 1/2 HDAC enzymes, was tested as a monotherapy in a phase 2 study of patients with relapsed DLBCL, but 16 of 18 enrolled patients experienced PD [74]. Here, HDAC9 is linked to diffuse large B-cell lymphoma.